ClinicalTrials.gg
CompletedNCT01791244RebiQoLUpdated Aug 24, 2017Results posted

A Phase 4 Study to Assess the Impact of Patient Support Program on Health Related Quality of Life and Adherence in Subjects With Relapsing-Remitting Multiple Sclerosis Administered Rebif® With the RebiSmart™ Device

A Phase 4 interventional study of Rebif® in Multiple Sclerosis and Relapsing-Remitting, sponsored by Merck KGaA, Darmstadt, Germany. Completed at 14 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-08-24.

Sponsored by Merck KGaA, Darmstadt, Germany · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
93
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 34 studies testing Interferon beta-1a in Multiple Sclerosis — none open to participants now, none under way, none of them phase 3. Interferon beta-1a · Multiple Sclerosis.

Enrollment
17th of 34
93 · median 85
Started
2013
the only one that year
Phase 4
15 of 34
none open now
Registered
29th of 34
by date
Lead sponsor
6 of 34
Merck KGaA, Darmstadt, Germany

Among the 34 studies testing Interferon beta-1a in Multiple Sclerosis, this one is the 17th largest by enrollment, is the only one that started in 2013, is one of 15 in phase 4, and was the 29th registered.

Multiple Sclerosis

3,271 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.

Browse Multiple Sclerosis studies →

Open to participants now

None of the 34 studies testing Interferon beta-1a in Multiple Sclerosis is open now. The open studies under Multiple Sclerosis, anywhere →

About Interferon beta-1a

Interferon beta-1a: first FDA approval 1996 (AVONEX), first EMA approval 1997. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 433 Multiple Sclerosis studies recruiting now, 163 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 96 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 34 studies testing Interferon beta-1a in Multiple Sclerosis as a file.
02

Study summary

This is a randomized, comparative, and multicenter study to assess the impact of a patient support program (MinSupport Plus) on health related quality of life (HRQoL) and adherence in subjects with relapsing-remitting multiple sclerosis administered Rebif® with the RebiSmart™ device.

03

Conditions studied

  • Multiple Sclerosis
  • Relapsing-Remitting

Browse trials for

Keywords

  • Multiple Sclerosis
  • Relapsing-Remitting
  • Rebif
  • RebiSmart
  • Patient support program
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female, aged 18 or older
  • A diagnosis of relapsing-remitting multiple sclerosis according to the revised McDonald Criteria (2010)
  • Treatment with Rebif® 22 or 44 mcg subcutaneously three times a week in accordance to the Summary of product characteristics
  • Rebif® administered by the RebiSmart™ device
  • Provided a signed form

Exclusion criteria

Exclusion Criteria:

  • Has received any components, except for technical support, of MinSupport Plus prior to study entry
  • Has difficulty reading and/or understanding Swedish
  • Has a mental condition rendering the subject unable to understand the nature, scope and possible consequences of the study, and/or evidence of an uncooperative attitude
  • No access to computer
  • Participation in another clinical study
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
93 participants (actual)

Study arms

  • Active comparator
    Technical support for the RebiSmart™ device

    Subjects will be administered Rebif® by the RebiSmart™ device at a dose of either 22 or 44 microgram (mcg) subcutaneously (SC) 3 times a week in accordance to the summary of product characteristics (SPC) along with technical support for RebiSmart.

    Drug: Rebif®

  • Experimental
    Subject support program (MinSupport Plus)

    Subjects will be administered Rebif® by the RebiSmart™ device at a dose of either 22 or 44 mcg SC 3 times a week in accordance to the SPC along with subject support program MinSupport Plus which includes technical support for RebiSmart™ device, personal coaching regarding treatment and understanding of the disease, lifestyle guide and web support.

    Drug: Rebif®

Interventions

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Multiple Sclerosis Impact Scale-29 (MSIS-29) Psychological Score at Month 12

    Multiple Sclerosis Impact Scale-29 (MSIS-29) is a validated MS specific questionnaire consisting of 29 questions of which 20 addressed the physical impact component and 9 assessed the psychological impact. A combined score can be generated, or both components can be reported separately. The psychological wellbeing assessment portion of the MSIS-29 was comprised of 9 questions in which subjects rate the impact of MS on their day-to-day life from 1=no impact to 5=extreme impact. The total Psychological Score was calculated using following formula: sum of score for 9 questions - 9/0.36. The total score range ranges from 0-100 where, lower total score indicates less psychologically-related impact while a higher total score indicates greater psychologically-related impact on a subject's functioning.

    Time frame: Baseline and Month 12

Secondary outcomes

  1. Change From Baseline in Multiple Sclerosis Impact Scale-29 (MSIS-29) Psychological Score at Month 6

    Multiple Sclerosis Impact Scale-29 (MSIS-29) is a validated MS specific questionnaire consisting of 29 questions of which 20 addressed the physical impact component and 9 assessed the psychological impact. A combined score can be generated, or both components can be reported separately. The psychological wellbeing assessment portion of the MSIS-29 was comprised of 9 questions in which subjects rate the impact of MS on their day-to-day life from 1=no impact to 5=extreme impact. The total Psychological Score was calculated using following formula: sum of score for 9 questions - 9/0.36. The total score range ranges from 0-100 where, lower total score indicates less psychologically-related impact while a higher total score indicates greater psychologically-related impact on a subject's functioning.

    Time frame: Baseline and Month 6

  2. Change From Baseline in Multiple Sclerosis Impact Scale-29 (MSIS-29) Total Score at Month 6 and 12

    Multiple Sclerosis Impact Scale-29 (MSIS-29) is a validated MS specific questionnaire consisting of 29 questions of which 20 addressed the physical impact component and 9 assessed the psychological impact. A combined score can be generated, or both components can be reported separately. The total score of the MSIS-29 was comprised of all the 29 questions in which subjects rate the impact of MS on their day-to-day life from 1=no impact to 5=extreme impact. The total Score was calculated using following formula: sum of score for 29 questions - 29/1.45. The total score range ranges from 0-100 where, lower total score indicates less psychologically-related impact while a higher total score indicates greater psychologically-related impact on a subject's functioning.

    Time frame: Baseline, Month 6 and 12

  3. Change From Baseline in Euro Quality of Life Questionnaire With 5 Questions Alternatives (EQ5D-5L) Summary Score at Month 6 and 12

    Quality of life was assessed using the EQ5D-5L score, which is one of the most widely used generic index measures of health-related quality of life. It consists of a 5-item descriptive system that measures 5 dimensions of health, including mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension comprises 5 levels with corresponding numeric scores ranging from 1 (no problems) through 5 (extreme problems) in which 1= no problems, 2= slight problems, 3= moderate problems, 4= severe problems, and 5= extreme problems. A unique EQ5D-5L health state was defined by combining the numeric level scores for each of the 5 dimensions and the total score ranges from 5 to 25. An increase in the EQ5D-5L total score indicates worsening.

    Time frame: Baseline, Month 6 and 12

  4. Change From Baseline in Euro Quality of Life Questionnaire With 5 Questions Alternatives (EQ5D-5L) Visual Analogue Scale (VAS) Scale at Month 6 and 12

    EQ-5D-5L VAS was used to record a subject's rating for his/her current health-related quality of life state and captured on a vertical VAS (0-100), where 0 = worst imaginable health state and 100 = best imaginable health state.

    Time frame: Baseline, Month 6 and 12

  5. Percentage of Subjects With Treatment Adherence at Month 6 and 12

    According to the World Health Organisation (WHO), treatment adherence is defined as both compliance (taking the medication in the correct dose and according to the schedule prescribed) and persistency (maintenance of the drug regimen over the long-term). Percentage of subjects with \<10% missed injections (measured with the software RDS 2.0) during 6 and 12 months were reported.

    Time frame: Month 6 and 12

  6. Change From Baseline in Fatigue Severity Scale (FSS) Score at Month 6 and 12

    Fatigue Severity Scale (FSS) is a method of evaluating fatigue in multiple sclerosis and is designed to differentiate fatigue from clinical depression, since both share some of the same symptoms. The Fatigue Severity Scale is a 9-item questionnaire developed to assess the level of fatigue due to neurological disease, were each assessed on a 1-7 scale (1= no fatigue and 7= severe fatigue). The total score was calculated as the average of individual 9-items and ranged from 1 to 7 with a higher value indicating greater impairment due to fatigue.

    Time frame: Baseline, Month 6 and 12

  7. Change From Baseline in Modified Fatigue Impact Scale Score at Month 6 and 12

    The Modified Fatigue Impact Scale is a list of 21 statements describing how fatigue may affect a person's functioning. Answers ranging from 0 (Never) to 4 (Almost always). A total score ranged from a possible 0 (no fatigue impact) to 84 (almost always impacted by fatigue). A lower total score indicates less fatigue-related impact while a higher total score indicates greater fatigue-related impact on a subject's functioning.

    Time frame: Baseline, Month 6 and 12

  8. Change From Baseline in Modified Fatigue Impact Scale Index at Month 6 and 12

    The Modified Fatigue Impact Index assesses fatigue- severity, distress, or degree of interference. Modified Fatigue Impact Scale Index was expressed in terms of percentage and ranged from 0% (no fatigue) to 100% (almost always impacted by fatigue).

    Time frame: Baseline, Month 6 and 12

  9. Change From Baseline in Hospital Anxiety and Depression Scale (HADS) Score at Month 6 and 12

    Hospital Anxiety and Depression Scale (HADS) was used to measure depression and anxiety in patients. The scale was limited to 14 questions, a practical tool for identifying and quantifying the two most common forms psychological disturbances in medical subjects. 7 of the items relate to anxiety and 7 relate to depression. Each item on the questionnaire was scored from 0-3 giving a total score between 0 and 21 for either anxiety or depression where higher score indicates more anxiety/depression.

    Time frame: Baseline, Month 6 and 12

  10. Number of Subjects With Working Ability at Month 12

    Working ability was assessed by measuring the number of subjects for the following categories: 1) Subjects with full sickness/disability pension, 2) Subjects who were employed or had their own business, 3) Subjects who were retired, 4) Subjects who were studying, 5) None of the above.

    Time frame: Month 12

  11. Percentage of Subjects With Adverse Events (AE) up to Month 12

    AE was defined as any untoward medical occurrence which does not necessarily have a causal relationship with this the study drug. An AE was defined as any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of study drug, whether or not considered related to the study drug. A serious AE was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. Treatment Emergent Adverse Events (TEAEs) include both Serious TEAEs and non-serious TEAEs.

    Time frame: Baseline up to Month 12

  12. Number of Subjects With Response Based on Lifestyle Questionnaire for (MinSupport Plus) at Month 6 and 12

    Lifestyle Questionnaire was used to assess the quality of life for subjects based on following parameters: Stress, Alcohol, Cost, Physical Aspect, Sleep, Activity and Smoking. Subjects provided their responses on the basis of three color codes: Green, Orange and Red, where Green refers to - no problem; Orange refers to - some problem and red refers to - definite/debilitating problem.

    Time frame: Month 6 and 12

  13. Number of Subjects With Response Based on Subject Satisfaction Questionnaire at Month 12

    The subject satisfaction questionnaire was defined as satisfaction with overall treatment and support from health care providers during the last 12 months. Subjects were asked to rate their satisfaction by choosing either "Very discontented, discontented, contented or Very contented".

    Time frame: Month 12

  14. Number of Subjects With Response Based on Health Care Personnel Satisfaction Questionnaire at Month 12

    The subject satisfaction questionnaire was defined as satisfaction with overall treatment and support from health care providers during the last 12 months. Subjects were asked to rate their satisfaction by choosing either "Very unsatisfied, unsatisfied, satisfied or very satisfied".

    Time frame: Month 12

  15. Number of Subjects With Lifestyle Goals for MinSupport Plus at Month 12

    Subjects defined up to 4 personal lifestyle goals during the first study week. Subjects completed the following questions related to lifestyle goals achieved during this study: 1. Was the goal achieved? (Yes/No) 2. If yes, better than expected or achieved as expected? 3. If better than expected, a lot or a little better than expected? 4. If no, a little or a lot less than expected?

    Time frame: Month 12

07

Results

Posted Jul 12, 2017

Participant flow

Participant flow — Overall Study
MilestoneSubject Support Program (MinSupport Plus)Technical Support for the RebiSmart™ Device
Started4647
Intent to treat (itt)3839
Completed3129
Not completed1518
Withdrew: Adverse event57
Withdrew: Insufficient clinical response1010
Withdrew: Laboratory abnormality01

Outcome measures

PrimaryChange From Baseline in Multiple Sclerosis Impact Scale-29 (MSIS-29) Psychological Score at Month 12

Multiple Sclerosis Impact Scale-29 (MSIS-29) is a validated MS specific questionnaire consisting of 29 questions of which 20 addressed the physical impact component and 9 assessed the psychological impact. A combined score can be generated, or both components can be reported separately. The psychological wellbeing assessment portion of the MSIS-29 was comprised of 9 questions in which subjects rate the impact of MS on their day-to-day life from 1=no impact to 5=extreme impact. The total Psychological Score was calculated using following formula: sum of score for 9 questions - 9/0.36. The total score range ranges from 0-100 where, lower total score indicates less psychologically-related impact while a higher total score indicates greater psychologically-related impact on a subject's functioning.

Time frame:
Baseline and Month 12
Reported as:
Mean · units on a scale
Change From Baseline in Multiple Sclerosis Impact Scale-29 (MSIS-29) Psychological Score at Month 12
units on a scaleSubject Support Program (MinSupport Plus)Technical Support for the RebiSmart™ Device
Baseline35.19 ± 24.3830.48 ± 20.94
Change at Month 12-2.44 ± 19.38-3.04 ± 19.76
Statistical analysis
  • Subject Support Program (MinSupport Plus) vs Technical Support for the RebiSmart™ Device · linear mixed model · p = 0.9148 · Adjusted mean difference: 0.48 · 95% CI -8.30 to 9.25
SecondaryChange From Baseline in Multiple Sclerosis Impact Scale-29 (MSIS-29) Psychological Score at Month 6

Multiple Sclerosis Impact Scale-29 (MSIS-29) is a validated MS specific questionnaire consisting of 29 questions of which 20 addressed the physical impact component and 9 assessed the psychological impact. A combined score can be generated, or both components can be reported separately. The psychological wellbeing assessment portion of the MSIS-29 was comprised of 9 questions in which subjects rate the impact of MS on their day-to-day life from 1=no impact to 5=extreme impact. The total Psychological Score was calculated using following formula: sum of score for 9 questions - 9/0.36. The total score range ranges from 0-100 where, lower total score indicates less psychologically-related impact while a higher total score indicates greater psychologically-related impact on a subject's functioning.

Time frame:
Baseline and Month 6
Reported as:
Mean · units on a scale
Change From Baseline in Multiple Sclerosis Impact Scale-29 (MSIS-29) Psychological Score at Month 6
units on a scaleSubject Support Program (MinSupport Plus)Technical Support for the RebiSmart™ Device
Baseline35.19 ± 24.3830.48 ± 20.94
Change at Month 6-1.36 ± 16.82-1.59 ± 13.26
SecondaryChange From Baseline in Multiple Sclerosis Impact Scale-29 (MSIS-29) Total Score at Month 6 and 12

Multiple Sclerosis Impact Scale-29 (MSIS-29) is a validated MS specific questionnaire consisting of 29 questions of which 20 addressed the physical impact component and 9 assessed the psychological impact. A combined score can be generated, or both components can be reported separately. The total score of the MSIS-29 was comprised of all the 29 questions in which subjects rate the impact of MS on their day-to-day life from 1=no impact to 5=extreme impact. The total Score was calculated using following formula: sum of score for 29 questions - 29/1.45. The total score range ranges from 0-100 where, lower total score indicates less psychologically-related impact while a higher total score indicates greater psychologically-related impact on a subject's functioning.

Time frame:
Baseline, Month 6 and 12
Reported as:
Mean · units on a scale
Change From Baseline in Multiple Sclerosis Impact Scale-29 (MSIS-29) Total Score at Month 6 and 12
units on a scaleSubject Support Program (MinSupport Plus)Technical Support for the RebiSmart™ Device
Baseline21.81 ± 21.5518.01 ± 16.61
Change at Month 60.56 ± 9.350.14 ± 11.19
Change at Month 121.00 ± 11.340.00 ± 10.45
SecondaryChange From Baseline in Euro Quality of Life Questionnaire With 5 Questions Alternatives (EQ5D-5L) Summary Score at Month 6 and 12

Quality of life was assessed using the EQ5D-5L score, which is one of the most widely used generic index measures of health-related quality of life. It consists of a 5-item descriptive system that measures 5 dimensions of health, including mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension comprises 5 levels with corresponding numeric scores ranging from 1 (no problems) through 5 (extreme problems) in which 1= no problems, 2= slight problems, 3= moderate problems, 4= severe problems, and 5= extreme problems. A unique EQ5D-5L health state was defined by combining the numeric level scores for each of the 5 dimensions and the total score ranges from 5 to 25. An increase in the EQ5D-5L total score indicates worsening.

Time frame:
Baseline, Month 6 and 12
Reported as:
Mean · units on a scale
Change From Baseline in Euro Quality of Life Questionnaire With 5 Questions Alternatives (EQ5D-5L) Summary Score at Month 6 and 12
units on a scaleSubject Support Program (MinSupport Plus)Technical Support for the RebiSmart™ Device
Baseline8.84 ± 3.378.03 ± 2.30
Change at Month 60.18 ± 2.170.10 ± 1.76
Change at Month 120.05 ± 2.51-0.08 ± 1.86
SecondaryChange From Baseline in Euro Quality of Life Questionnaire With 5 Questions Alternatives (EQ5D-5L) Visual Analogue Scale (VAS) Scale at Month 6 and 12

EQ-5D-5L VAS was used to record a subject's rating for his/her current health-related quality of life state and captured on a vertical VAS (0-100), where 0 = worst imaginable health state and 100 = best imaginable health state.

Time frame:
Baseline, Month 6 and 12
Reported as:
Mean · units on a scale
Change From Baseline in Euro Quality of Life Questionnaire With 5 Questions Alternatives (EQ5D-5L) Visual Analogue Scale (VAS) Scale at Month 6 and 12
units on a scalePatient Support Program (MinSupport Plus)Technical Support for the RebiSmart™ Device
Baseline71.18 ± 20.7071.49 ± 16.61
Change at Month 6-0.71 ± 11.36-3.38 ± 19.35
Change at Month 12-0.84 ± 16.07-2.31 ± 20.60
SecondaryPercentage of Subjects With Treatment Adherence at Month 6 and 12

According to the World Health Organisation (WHO), treatment adherence is defined as both compliance (taking the medication in the correct dose and according to the schedule prescribed) and persistency (maintenance of the drug regimen over the long-term). Percentage of subjects with \<10% missed injections (measured with the software RDS 2.0) during 6 and 12 months were reported.

Time frame:
Month 6 and 12
Reported as:
Number · Percentage of Subjects
Percentage of Subjects With Treatment Adherence at Month 6 and 12
Percentage of SubjectsSubject Support Program (MinSupport Plus)Technical Support for the RebiSmart™ Device
At Month 671.0564.10
At Month 1265.7953.85
SecondaryChange From Baseline in Fatigue Severity Scale (FSS) Score at Month 6 and 12

Fatigue Severity Scale (FSS) is a method of evaluating fatigue in multiple sclerosis and is designed to differentiate fatigue from clinical depression, since both share some of the same symptoms. The Fatigue Severity Scale is a 9-item questionnaire developed to assess the level of fatigue due to neurological disease, were each assessed on a 1-7 scale (1= no fatigue and 7= severe fatigue). The total score was calculated as the average of individual 9-items and ranged from 1 to 7 with a higher value indicating greater impairment due to fatigue.

Time frame:
Baseline, Month 6 and 12
Reported as:
Mean · units on a scale
Change From Baseline in Fatigue Severity Scale (FSS) Score at Month 6 and 12
units on a scaleSubject Support Program (MinSupport Plus)Technical Support for the RebiSmart™ Device
Baseline3.93 ± 1.753.98 ± 1.72
Change at Month 60.15 ± 0.790.05 ± 0.81
Change at Month 120.13 ± 0.890.08 ± 1.09
SecondaryChange From Baseline in Modified Fatigue Impact Scale Score at Month 6 and 12

The Modified Fatigue Impact Scale is a list of 21 statements describing how fatigue may affect a person's functioning. Answers ranging from 0 (Never) to 4 (Almost always). A total score ranged from a possible 0 (no fatigue impact) to 84 (almost always impacted by fatigue). A lower total score indicates less fatigue-related impact while a higher total score indicates greater fatigue-related impact on a subject's functioning.

Time frame:
Baseline, Month 6 and 12
Reported as:
Mean · units on a scale
Change From Baseline in Modified Fatigue Impact Scale Score at Month 6 and 12
units on a scaleSubject Support Program (MinSupport Plus)Technical Support for the RebiSmart™ Device
Baseline29.74 ± 20.5031.08 ± 19.08
Change at Month 63.89 ± 10.812.27 ± 9.78
Change at Month 123.75 ± 10.431.78 ± 10.65
SecondaryChange From Baseline in Modified Fatigue Impact Scale Index at Month 6 and 12

The Modified Fatigue Impact Index assesses fatigue- severity, distress, or degree of interference. Modified Fatigue Impact Scale Index was expressed in terms of percentage and ranged from 0% (no fatigue) to 100% (almost always impacted by fatigue).

Time frame:
Baseline, Month 6 and 12
Reported as:
Mean · Percentage of fatigue
Change From Baseline in Modified Fatigue Impact Scale Index at Month 6 and 12
Percentage of fatiguePatient Support Program (MinSupport Plus)Technical Support for the RebiSmart™ Device
Baseline35.40 ± 24.4137.00 ± 22.72
Change at Month 64.63 ± 12.872.71 ± 11.64
Change at Month 124.47 ± 12.422.12 ± 12.68
SecondaryChange From Baseline in Hospital Anxiety and Depression Scale (HADS) Score at Month 6 and 12

Hospital Anxiety and Depression Scale (HADS) was used to measure depression and anxiety in patients. The scale was limited to 14 questions, a practical tool for identifying and quantifying the two most common forms psychological disturbances in medical subjects. 7 of the items relate to anxiety and 7 relate to depression. Each item on the questionnaire was scored from 0-3 giving a total score between 0 and 21 for either anxiety or depression where higher score indicates more anxiety/depression.

Time frame:
Baseline, Month 6 and 12
Reported as:
Mean · units on a scale
Change From Baseline in Hospital Anxiety and Depression Scale (HADS) Score at Month 6 and 12
units on a scaleSubject Support Program (MinSupport Plus)Technical Support for the RebiSmart™ Device
Baseline (Anxiety Score)6.13 ± 4.145.62 ± 3.21
Change at Month 6 (Anxiety Score)-0.21 ± 2.92-0.56 ± 2.78
Change at Month 12 (Anxiety Score)-0.42 ± 3.48-0.18 ± 3.26
Baseline (Depression Score)4.26 ± 3.493.72 ± 2.77
Change at Month 6 (Depression Score)0.61 ± 2.430.46 ± 2.85
Change at Month 12 (Depression Score)0.42 ± 3.610.74 ± 3.14
SecondaryNumber of Subjects With Working Ability at Month 12

Working ability was assessed by measuring the number of subjects for the following categories: 1) Subjects with full sickness/disability pension, 2) Subjects who were employed or had their own business, 3) Subjects who were retired, 4) Subjects who were studying, 5) None of the above.

Time frame:
Month 12
Reported as:
Number · Subjects
Number of Subjects With Working Ability at Month 12
SubjectsSubject Support Program (MinSupport Plus)Technical Support for the RebiSmart™ Device
Subjects with full sickness/disability pension45
Subjects who were employed or had own business2225
Subject who were retired22
Subject who were studying32
None of the above11
SecondaryPercentage of Subjects With Adverse Events (AE) up to Month 12

AE was defined as any untoward medical occurrence which does not necessarily have a causal relationship with this the study drug. An AE was defined as any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of study drug, whether or not considered related to the study drug. A serious AE was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. Treatment Emergent Adverse Events (TEAEs) include both Serious TEAEs and non-serious TEAEs.

Time frame:
Baseline up to Month 12
Reported as:
Number · Percentage of Subjects
Percentage of Subjects With Adverse Events (AE) up to Month 12
Percentage of SubjectsSubject Support Program (MinSupport Plus)Technical Support for the RebiSmart™ Device
Percentage of Subjects With Adverse Events (AE) up to Month 1245.761.7
SecondaryNumber of Subjects With Response Based on Lifestyle Questionnaire for (MinSupport Plus) at Month 6 and 12

Lifestyle Questionnaire was used to assess the quality of life for subjects based on following parameters: Stress, Alcohol, Cost, Physical Aspect, Sleep, Activity and Smoking. Subjects provided their responses on the basis of three color codes: Green, Orange and Red, where Green refers to - no problem; Orange refers to - some problem and red refers to - definite/debilitating problem.

Time frame:
Month 6 and 12
Reported as:
Number · Subjects
Number of Subjects With Response Based on Lifestyle Questionnaire for (MinSupport Plus) at Month 6 and 12
SubjectsSubject Support Program (MinSupport Plus)
Month 6: Stress: Green; n= 302
Month 6: Stress: Orange; n= 303
Month 6: Stress: Red; n= 303
Month 12: Stress: Green; n= 313
Month 12: Stress: Orange; n= 312
Month 12: Stress: Red; n= 312
Month 6: Alcohol: Green; n= 307
Month 6: Alcohol: Orange; n= 301
Month 6: Alcohol: Red; n= 301
Month 12: Alcohol: Green; n= 326
Month 12: Alcohol: Orange; n= 326
Month 12: Alcohol: Red; n= 326
Month 6: Cost: Green; n= 304
Month 6: Cost: Orange; n= 304
Month 6: Cost: Red; n= 304
Month 12: Cost: Green; n= 323
Month 12: Cost: Orange; n= 323
Month 12: Cost: Red; n= 323
Month 6: Physical: Green; n= 305
Month 6: Physical: Orange; n= 302
Month 6: Physical: Red; n= 301
Month 12: Physical: Green; n= 325
Month 12: Physical: Orange; n= 321
Month 12: Physical: Red; n= 321
Month 6: Activity: Green; n= 305
Month 6: Activity: Orange; n= 302
Month 6: Activity: Red; n= 301
Month 12: Activity: Green; n= 325
Month 12: Activity: Orange; n= 321
Month 12: Activity: Red; n= 321
Month 6: Sleep: Green; n= 303
Month 6: Sleep: Orange; n= 304
Month 6: Sleep: Red; n= 301
Month 12: Sleep: Green; n= 323
Month 12: Sleep: Orange; n= 322
Month 12: Sleep: Red; n= 321
Month 6: Smoking: Green; n= 315
Month 6: Smoking: Orange; n= 311
Month 6: Smoking: Red; n= 311
Month 12: Smoking: Green; n= 325
Month 12: Smoking: Orange; n= 321
Month 12: Smoking: Red; n= 321
SecondaryNumber of Subjects With Response Based on Subject Satisfaction Questionnaire at Month 12

The subject satisfaction questionnaire was defined as satisfaction with overall treatment and support from health care providers during the last 12 months. Subjects were asked to rate their satisfaction by choosing either "Very discontented, discontented, contented or Very contented".

Time frame:
Month 12
Reported as:
Number · Subjects
Number of Subjects With Response Based on Subject Satisfaction Questionnaire at Month 12
SubjectsSubject Support Program (MinSupport Plus)Technical Support for the RebiSmart™ Device
Very discontented12
Discontented65
Contented1311
Very contented1015
SecondaryNumber of Subjects With Response Based on Health Care Personnel Satisfaction Questionnaire at Month 12

The subject satisfaction questionnaire was defined as satisfaction with overall treatment and support from health care providers during the last 12 months. Subjects were asked to rate their satisfaction by choosing either "Very unsatisfied, unsatisfied, satisfied or very satisfied".

Time frame:
Month 12
Reported as:
Number · Subjects
Number of Subjects With Response Based on Health Care Personnel Satisfaction Questionnaire at Month 12
SubjectsSubject Support Program (MinSupport Plus)Technical Support for the RebiSmart™ Device
Very unsatisfied01
Unsatisfied20
Satisfied109
Very satisfied63
SecondaryNumber of Subjects With Lifestyle Goals for MinSupport Plus at Month 12

Subjects defined up to 4 personal lifestyle goals during the first study week. Subjects completed the following questions related to lifestyle goals achieved during this study: 1. Was the goal achieved? (Yes/No) 2. If yes, better than expected or achieved as expected? 3. If better than expected, a lot or a little better than expected? 4. If no, a little or a lot less than expected?

Time frame:
Month 12
Reported as:
Number · Subjects
Number of Subjects With Lifestyle Goals for MinSupport Plus at Month 12
SubjectsSubject Support Program (MinSupport Plus)
Goal 1(G1) : Goal Achieved; n= 3818
G1: Goal not Achieved; n= 384
G1: Missing; n= 3816
G1 Achieved: Better than Expected; n= 185
G1 Achieved: As Expected; n= 1810
G1 Achieved: Missing; n= 183
G1Acheived:Better than Expected:Little Better;n= 54
G1Achieved:Better than expected:Lot better; n= 50
G1Achieved:Better than Expected: Missing; n= 51
G1 not Achieved: Little Less; n= 41
G1 not Achieved: Lot Less; n= 40
G1 not Achieved: Missing; n= 43
Goal 2 (G2): Goal Achieved; n= 383
G2: Goal not Achieved; n= 381
G2: Missing; n= 3834
G2 Achieved: Better than Expected; n= 32
G2 Achieved: As Expected; n= 30
G2 Achieved: Missing; n= 31
G2Achieved:Better than Expected:Little Better;n= 21
G2 Achieved: Better than Expected:Lot Better; n= 21
G2 Achieved: Better than Expected: Missing; n= 20
G2 not Achieved: Little Less; n= 10
G2 not Achieved: Lot Less; n= 11
G2 not Achieved: Missing; n= 10
Goal 3 (G3): Goal Achieved; n= 380
G3: Goal not Achieved; n= 381
G3: Missing; n= 3837
G3 Achieved: As Expected; n= 00
G3 Achieved: Better than Expected; n= 00
G3 Achieved: Missing; n= 00
G3 Achieved:Better than Expected:Little Better;n=00
G3 Achieved:Better than Expected: Lot Better;n=00
G3 Achieved: Better than Expected: Missing; n= 00
G3 not Achieved: Little Less; n= 11
G3 not Achieved: Lot Less; n= 10
G3 not Achieved: Missing; n= 10
Goal 4 (G4): Goal Achieved; n= 380
G4: Goal not Achieved; n= 381
G4: Missing; n= 3837
G4 Achieved: Better than Expected; n= 00
G4 Achieved: As Expected; n= 00
G4 Achieved: Missing; n= 00
G4 Expected:Little Better; n= 00
G4Achieved:Better than expected:Lot Better; n= 00
G4 Achieved: Better than Expected: Missing; n= 00
G4 not Achieved: Little Less; n= 10
G4 not Achieved: Lot Less; n= 10
G4 not Achieved: Missing; n= 11

Adverse events

Collected over Baseline up to Month 12. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Patient Support Program (MinSupport Plus)—2/46 (4.3%)19/46 (41.3%)
Technical Support for the RebiSmart™ Device—0/47 (0%)29/47 (61.7%)
Most frequent serious events
Most frequent serious events
EventPatient Support Program (MinSupport Plus)Technical Support for the RebiSmart™ Device
Urinary tract infectionInfections and infestations2/460/47
PneumoniaInfections and infestations1/460/47
Most frequent other events
Showing 10 of 46
Most frequent other events
EventPatient Support Program (MinSupport Plus)Technical Support for the RebiSmart™ Device
Hepatic enzyme increasedInvestigations1/465/47
HeadacheNervous system disorders2/463/47
Administration site painGeneral disorders2/460/47
FatigueGeneral disorders2/461/47
Influenza like illnessGeneral disorders2/462/47
NasopharyngitisInfections and infestations2/461/47
Urinary tract infectionInfections and infestations2/460/47
Multiple sclerosis relapseNervous system disorders2/462/47
InsomniaPsychiatric disorders2/460/47
DepressionPsychiatric disorders1/462/47

Baseline characteristics

The Intent-to-Treat (ITT) population included all subjects randomized into the trial and have completed at least 1 post-baseline assessment of the questionnaires.

Age, Customized
Age, Customized(Participants)Subject Support Program (MinSupport Plus)Technical Support for the RebiSmart™ DeviceTotal
Between 18 to 72 years383977
Greater than (>) 72 years000
Sex: Female, Male
Sex: Female, Male(Participants)Subject Support Program (MinSupport Plus)Technical Support for the RebiSmart™ DeviceTotal
Female242448
Male141529
08

Study locations

14 sites
  • Please contact the Merck Communications Service for Recruiting locations
    Darmstadt, Germany
  • Research site
    Angered, Sweden
  • Research Site
    Danderyd, Sweden
  • Research Site
    Eksjö, Sweden
  • Research Site
    Gävle, Sweden
  • Research Site
    Karlstad, Sweden
  • Research Site
    KS Huddinge, Sweden
  • Research Site
    Linköping, Sweden
  • Research Site
    Malmö/Lund, Sweden
  • Research Site
    Motala, Sweden
  • Research Site
    Skövde, Sweden
  • Research Site
    Trollhättan, Sweden
  • Research site
    Ängelholm, Sweden
  • Research Site
    Örnsköldsvik, Sweden
09

References and documents

Publications

  • Landtblom AM, Guala D, Martin C, Olsson-Hau S, Haghighi S, Jansson L, Fredrikson S. RebiQoL: A randomized trial of telemedicine patient support program for health-related quality of life and adherence in people with MS treated with Rebif. PLoS One. 2019 Jul 5;14(7):e0218453. doi: 10.1371/journal.pone.0218453. eCollection 2019. PubMed 31276502 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2013 to primary completion in Feb 2016, 36 months.

Results were first posted in Jul 2017, 1 year 4 months after primary completion.

Of 36 industry-sponsored phase 4 interventional studies under Multiple Sclerosis, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 37. This study's 36 months is above that.

Counting every sponsor, half of 69 studies reached it within 34 months; a quarter within 23 and three quarters within 59.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 12, 2013
First posted
Feb 13, 2013
StartActual
Feb 28, 2013
Primary completionActual
Feb 29, 2016
CompletionActual
Feb 29, 2016
Results first posted
Jul 12, 2017
Last update
Aug 24, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 24, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01791244
Responsible party
Sponsor
First posted
Feb 13, 2013
Start date
Feb 28, 2013
Primary completion
Feb 29, 2016
Completion
Feb 29, 2016
Results posted
Jul 12, 2017
Last update
Aug 24, 2017
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Interferon beta-1a

Start the discussion